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Prevention of Hepatitis A Through
Active or Passive Immunization:
Recommendations of the Advisory Committee on
Immunization Practices (ACIP)
Summary
This report provides recommendations for use of the newly licensed hepatitis
A vaccines (HAVRIX,® manufactured by SmithKline Beecham Biologicals, and
VAQTA,® manufactured by Merck & Company, Inc.) in persons ≥2 years of age
and updates previous recommendations for use of immune globulin (IG) for pro-
tection against hepatitis A (superseding MMWR 1990;39[No. RR-2]:1–5). For
preexposure protection, hepatitis A vaccine can now be used instead of IG in
many circumstances; for postexposure prophylaxis, the recommendations for
IG use are unchanged.
INTRODUCTION
Until recently, the primary methods used for preventing hepatitis A have been hy-
gienic measures and passive immunization with immune globulin (IG) to provide
short-term preexposure or postexposure protection (1 ). The ability to grow hepatitis
A virus (HAV) in cell culture has resulted in the development of vaccines that prevent
HAV infection following preexposure immunization (2–4 ). For the individual, active
immunization can provide long-term protection against HAV infection; from a public
health perspective, active immunization provides the means to effectively control this
disease. The similarities between the epidemiology of hepatitis A and poliomyelitis
suggest that widespread vaccination of appropriate susceptible populations can
substantially lower disease incidence, eliminate virus transmission, and, ultimately,
eradicate HAV infection.
FEATURES OF HEPATITIS A
Clinical Illness
HAV, a 27-nm RNA agent classified as a picornavirus, can produce either asympto-
matic infection or symptomatic infection in humans after an average incubation
period of 28 days (range: 15–50 days) (5 ). The illness caused by HAV infection typi-
cally has an abrupt onset that can include fever, malaise, anorexia, nausea, abdominal
discomfort, dark urine, and jaundice. The likelihood of having symptoms with HAV
infection is related to the person’s age. In children <6 years of age, most (70%) infec-
tions are asymptomatic; if illness does occur, it is not usually accompanied by
jaundice (6 ). Among older children and adults, infection is usually symptomatic, with
jaundice occurring in >70% of patients (7 ). Signs and symptoms usually last
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<2 months, although 10%–15% of persons have prolonged or relapsing disease last-
ing up to 6 months (8 ).
In persons who have either symptomatic or asymptomatic infection, HAV replicates
in the liver, is excreted in bile, and is shed in the stool. Peak infectivity of infected
persons occurs during the 2-week period before onset of jaundice or elevation of liver
enzymes, when the concentration of virus in stool is highest (9,10 ). The concentration
of virus in stool declines after jaundice appears (9,10 ). Children and infants can shed
HAV for longer periods than do adults, up to several months after the onset of clinical
illness (11 ). Chronic shedding of HAV in feces does not occur; however, shedding may
occur in persons who have relapsing illness (12 ).
Diagnosis
Hepatitis A cannot be differentiated from other types of viral hepatitis based on
clinical or epidemiologic features alone. Serologic testing to detect IgM antibody to
the capsid proteins of HAV (IgM anti-HAV) is required to confirm a diagnosis of acute
HAV infection. In most persons, IgM anti-HAV becomes detectable 5–10 days after ex-
posure and can persist for up to 6 months after infection (13 ). IgG anti-HAV, which
appears early in the course of infection, remains detectable for the person’s lifetime
and confers lifelong protection against the disease (14 ). Commercial diagnostic tests
are available for the detection of IgM and total (IgM and IgG) anti-HAV in serum.
EPIDEMIOLOGY OF HAV INFECTION
Routes of Transmission
HAV infection is acquired primarily by the fecal-oral route by either person-to-
person contact or ingestion of contaminated food or water. Viremia occurs during the
prodromal phase of the illness, and HAV has been transmitted on rare occasions by
transfusion (15 ). In experimentally infected animals, HAV has been detected in saliva
during the incubation period; however, transmission by saliva has not been demon-
strated (16 ).
Depending on conditions, HAV can be stable in the environment for months (17 ).
Heating foods at temperatures >185 F (85 C) for 1 minute or disinfecting surfaces with
a 1:100 dilution of sodium hypochlorite (i.e., household bleach) in tap water is neces-
sary to inactivate HAV (18 ).
Surveillance and Seroprevalence Data
In the United States, cyclic increases in the incidence of hepatitis A have occurred
approximately every decade; the last nationwide increase occurred in 1989 (19 ). Be-
tween epidemics, hepatitis A continues to occur at relatively high rates. In 1994, a total
of 26,796 cases were reported to CDC’s National Notifiable Diseases Surveillance
System (NNDSS) (20 ). After the data were corrected for underreporting and asympto-
matic infections, an estimated 80,000 cases and 134,000 infections occurred in 1994
(CDC, unpublished data). Hepatitis A incidence varies by race/ethnicity, with highest
rates among American Indians/Alaskan Natives and lowest rates among Asians; rates
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among Hispanics are higher than among non-Hispanics (Figure 1). Rates also are sub-
stantially higher in the western United States than in other U.S. regions. Racial/ethnic
and geographic differences in rates most likely reflect differences in socioeconomic
levels and resultant living conditions (e.g., crowding), which facilitate transmission of
HAV.
The highest rates of hepatitis A are among children 5–14 years of age (Figure 2).
Almost 30% of reported hepatitis A cases occur among children <15 years of age (21 ).
Presumably many more children have unrecognized, asymptomatic infection and can
be a source of infection for others (6,11 ).
The most frequently reported source of infection (22%–26%) is either house-
hold contact or sexual contact with a person who has hepatitis A (21 ). An additional
14%–16% of reported cases occur among children or employees in day care centers or
among contacts of children or employees in day care centers; 4%–6% occur among
international travelers; and another 2%–3% are associated with recognized food or
waterborne disease outbreaks (19,21 ). Person-to-person contact is thought to be the
source of infection in outbreaks among injecting- and noninjecting-drug users and
among men who have sex with men (22,23 ). Approximately 50% of persons with
hepatitis A do not have an identified source of infection (21 ).
In the United States, 33% of the population has serologic evidence of prior HAV
infection as determined by Phase 1 of the Third National Health and Nutrition Exami-
nation Survey (NHANES-III) conducted during 1988–1991 (CDC, unpublished data).
Anti-HAV prevalence is directly related to age: among children <10 years of age, the
prevalence is 10%; 20–29 years of age, 18%; 40–49 years of age, 49%; and >70 years of
age, 75%. Anti-HAV prevalence is highest among Mexican-Americans (67%), com-
pared with blacks (37%) and whites (29%). Anti-HAV prevalence is inversely related to
income.
Race/Ethnicity
American Indian/Non-Hispanic
Black
Non-Hispanic
White
Total
Alaskan Native
Asian Hispanic
10.3
4.6 5.5 6.4
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121.2
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20
30
110
120
130
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R
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e
*Per 100,000 population.
FIGURE 1. Rates* of reported hepatitis A cases, by race/ethnicity — United States,
1994
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Hepatitis A results in substantial morbidity with associated costs caused by medi-
cal care and work loss; 11%–22% of persons who have hepatitis A are hospitalized
(21 ). Adults who become ill lose an average of 27 days of work per illness (Table 1).
Health departments incur substantial costs in providing postexposure prophylaxis to
an average of 11 contacts per case (CDC, unpublished data). Average costs (direct and
indirect) of hepatitis A range from $1,817 to $2,459 per case for adults and from $433
to $1,492 per case for children <18 years of age (Table 1). In 1989, the estimated annual
cost (direct and indirect) of hepatitis A in the United States was >$200 million (24 ).
In the United States, an estimated 100 deaths occur each year as a result of fulmi-
nant hepatitis A. Data reported to CDC indicate that the case-fatality rate among
persons of all ages is approximately 0.3%. However, the risk for death is 1.8% among
adults >50 years of age; persons who have chronic liver disease have a high risk of
death from fulminant hepatitis A (25,26 ).
Communitywide Outbreaks
In the United States, most hepatitis A occurs through person-to-person transmis-
sion during communitywide outbreaks (27 ) when the highest rates of disease occur
among children, adolescents, and young adults. Outbreaks have been difficult to con-
trol despite enhanced awareness of preventive measures and postexposure
prophylaxis with IG. Experience during most communitywide outbreaks has indicated
that widespread postexposure prophylaxis with IG may slow HAV transmission but
does not stop the outbreak (28,29 ).
1983 1984 1985 1986 1987 1988 1989 1990 1991 1992 1993
0
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25–39 years
≤4 years
≥40 years
Year
R
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e
*Per 100,000 population
FIGURE 2. Rates* of reported hepatitis A cases, by age — United States, 1983–1993
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Categorizing communities that experience hepatitis A outbreaks can help deter-
mine whether to use hepatitis A vaccine to control or prevent communitywide out-
breaks. Communities that experience hepatitis A outbreaks can be considered as
either communities that have high rates of hepatitis A or communities that have inter-
mediate rates of hepatitis A, based on certain epidemiologic characteristics (e.g.,
age-specific rates of infection and temporal patterns of disease incidence) (Table 2). In
both types of communities, outbreaks usually have been difficult to control.
Communities That Have High Rates of Hepatitis A
Communities that have high rates of infection typically have epidemics of hepati-
tis A every 5–10 years that may last for several years, have high rates of disease,
and have few cases among persons >15 years of age (Table 2). Seroprevalence data
indicate that 30%-40% of children in these communities acquire infection before
5 years of age and almost all persons become infected before reaching young adult-
hood (29–31 ). These communities often are relatively well defined, either geo-
graphically or ethnically, and include American Indian, Alaskan Native, Pacific Is-
lander, and selected Hispanic and religious communities (29,30,32–34 ).
TABLE 1. Morbidity associated with hepatitis A, by source of data and year —
United States
Outcome
Source of Data (Year)
Washington State*
(1989–1990)
Sentinel counties†
(1991)
Hospitalization (%)
All ages 11 10§
Children and adolescents
(<18 years of age)  3  7
Adults (≥18 years of age) 13 14
Mean duration of hospitalization
days (range), all ages 4 (1–10) 2 (1–5)
Outpatient visits per case
Average number (range) 4 (0–18) 3 (1–11)
Work loss per case
Average days (range) 27 (0–180) 12 (0–40)
Contacts administered IG¶
per case
Average number 11 10
Average cost per case
Children and adolescents
(<18 years of age) $  433 $1,492
Adults (≥18 years of age) $2,459 $1,817
*TR Eng, CDC, unpublished data; based upon interviews of 144 patients; cost data based upon
a subset of 74 patients with complete cost information.
†Jefferson County, Alabama; Denver County, Colorado; Pierce County, Washington; CDC, un-
published data.
§Hospitalization data are for all hepatitis cases identified (N=287); other data are based on a
subset (N=76) in which no children <18 years of age were hospitalized.
¶Immune globulin.
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Communities That Have Intermediate Rates of Hepatitis A
In communities that have intermediate rates of hepatitis A, most disease occurs
among children, adolescents, and young adults, in contrast to communities that have
high rates of hepatitis A, in which the majority of cases occur among children
<15 years of age. Communities that have intermediate rates of hepatitis A often are
large metropolitan areas, and cases may be concentrated in specific census tracts or
neighborhoods (Table 2) (28,35 ). Overall disease rates during epidemic periods typi-
cally range from 50 to 200 cases/100,000 population per year; however, within some
census tracts, disease rates can be as high as those in communities that have high
rates of hepatitis A. Surveillance data indicate epidemics often occur at regular inter-
vals and persist for several years. However, some communities that have intermediate
rates of hepatitis A do not have periodic epidemics but instead have sustained ele-
vated rates of disease for many years. The epidemiologic factors associated with
these differences in disease patterns have not been determined.
During epidemic periods, hepatitis A rates generally increase among all age
groups, indicating widespread disease within the community (36 ). Occasionally dur-
ing outbreaks, the number of cases may increase among users of illegal drugs, men
who have sex with men, or children and employees in day care centers (6,36–38 ). By
examining local surveillance data, each community can determine if such groups rep-
resent a substantial source of HAV infection.
Data from some studies indicate that children with asymptomatic HAV infection can
be a substantial source of infection for older persons during communitywide out-
breaks. Data from a study in California among adults without an identified source of
infection indicate that 25% of their asymptomatic contacts <6 years of age were IgM
anti-HAV positive (CDC, unpublished data).
Groups at Increased Risk for Hepatitis A
The following groups are at increased risk for hepatitis A:
Travelers
Persons from developed countries who travel to developing countries are at sub-
stantial risk for acquiring hepatitis A (39 ). Such persons include tourists, military
personnel, missionaries, and others who work or study abroad in countries that have
TABLE 2. Features of communities that have high and intermediate rates of hepatitis A
Community
Anti-HAV
prevalence
Age of most
patients
Reported
annual incidence*
Outbreak
periodicity Populations Examples (reference)
High rate 30%–40%
 (<5 yrs of age)
70%–100%
(>15 yrs of
age)
5–14 yrs 700–1,000 5–10 yrs Well defined
geographically 
or ethnically
Alaskan Native
villages (33 )
American Indian
reservations (29 )
Selected Hispanic
communities (34 )
Selected religious
communities (3 )
Intermediate
rate
10%–25%
(<5 yrs of age)
<50%
(>15 yrs of
age)
5–29 yrs 50–200 May be
periodic
Less defined
than in
high-rate
communities
Zanesville, OH (28 )
Oklahoma (38 )
St. Louis, MO (35 )
Selected religious
communities (32 )
* Typical reported overall incidence per 100,000 population per year during epidemics, all ages.
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high or intermediate endemicity of hepatitis A (Figure 3). Data from prospective stud-
ies indicate that the risk among travelers who do not receive IG is 3/1,000–5/1,000 per
month of stay; among some travelers, the risk is higher (40 ). The risk varies according
to region visited and the length of stay. The risk for hepatitis A is increased even
among travelers who report that they observe measures to protect themselves
against enteric infection or stay only in urban areas or luxury hotels, or both (CDC,
unpublished data).
Men Who Have Sex with Men
Hepatitis A outbreaks among men who have sex with men have been reported fre-
quently. Recent outbreaks have occurred in urban areas in the United States, Canada,
and Australia (23 ). Data from prospective serosurveys have demonstrated rates of
HAV infection among men who have sex with men that are several-fold higher than
those among control populations (41,42 ).
Injecting-Drug Users
During the past decade, outbreaks have been reported among injecting-drug users
in the United States and in Europe (22,37,38 ). In the late 1980s, 10%–19% of persons
who had hepatitis A reported a history of injecting-drug use; however, in recent years,
<3% of infected persons have reported this behavior (21 ).
Persons Working with Nonhuman Primates
Outbreaks of hepatitis A have been reported among persons working with non-
human primates that are susceptible to HAV infection, including several Old World
and New World species (43,44 ). Primates that were infected were those that had been
born in the wild, not those that had been born and raised in captivity.
Anti-HAV Prevalence
High
Intermediate
Low
*Low, intermediate, and high.
†This map generalizes available data, and patterns may vary within countries.
FIGURE 3. Endemicity patterns* of hepatitis A virus infection worldwide†
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Risk for Hepatitis A Among Other Groups and Settings
Persons Who Have Chronic Liver Disease
Although not at increased risk for HAV infection, persons who have chronic liver
disease are at increased risk for fulminant hepatitis A (45 ). Data from death certifi-
cates indicate a high prevalence of chronic liver disease among persons who had
fulminant hepatitis A (46 ).
Persons Who Have Clotting-Factor Disorders
During 1992–1993, several outbreaks of hepatitis A were reported in Europe among
persons who had clotting-factor disorders who had been administered solvent-
detergent–treated factor VIII concentrates that presumably had been contaminated
from plasma donors incubating hepatitis A (47 ). In the United States, data from one
serologic study suggested that hemophilic patients may be at increased risk for HAV
infection (48 ). During 1995–1996, several patients who had clotting-factor disorders
reportedly developed hepatitis A after having been administered solvent-detergent–
treated factor VIII and factor IX concentrates (49 ).
Food-Service Establishments/Food Handlers
Foodborne hepatitis A outbreaks are relatively uncommon in the United States;
however, when they occur, intensive public health efforts are required for their control.
These outbreaks are usually associated with contamination of food during preparation
by an HAV-infected food handler (50 ), although food (e.g., shellfish) that has been
contaminated before reaching the food-service establishment has been associated
with some outbreaks (51–53 ). Although persons who work as food handlers have a
critical role in common-source foodborne HAV transmission, they are not at increased
risk for hepatitis A because of their occupation. In a study of hepatitis A cases in Wash-
ington State during 1987–1988, rates of hepatitis A among food handlers were found
to be similar to rates among the general population in the state (Trueman Sharp,
University of Washington, unpublished data).
Day Care Centers
Outbreaks among children attending day care centers and persons employed at
these centers have been recognized since the 1970s (54 ). Because infection among
children is usually mild or asymptomatic, outbreaks often are recognized only when
adult contacts (usually parents) become ill (6 ). Poor hygiene among children who
wear diapers and the handling and changing of diapers by staff contribute to the
spread of HAV infection; outbreaks rarely occur in day care centers in which care is
provided only to children who do not wear diapers.
Despite the occurrence of outbreaks when HAV is introduced into day care centers,
the results of serologic surveys do not indicate a substantially increased prevalence of
HAV infection among staff at day care centers compared with the prevalence among
control populations (55,56 ). Furthermore, the NHANES-III study did not indicate an
increased prevalence of HAV infection among children and adolescents who pre-
viously attended day care centers (CDC, unpublished data). Although outbreaks at
day care centers occasionally are the sources of outbreaks of hepatitis A within a
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community, disease within day care centers more commonly reflects extended trans-
mission in the community.
Health-Care Institutions
Nosocomial HAV transmission is rare. Outbreaks have occasionally been observed
in neonatal intensive-care units because of infants acquiring infection from transfused
blood and subsequently transmitting hepatitis A to other infants and staff (11,57,58 ).
Outbreaks of hepatitis A caused by transmission from adult patients to health-care
workers are usually associated with fecal incontinence, although most hospitalized
patients who have hepatitis A are admitted after onset of jaundice when they are be-
yond the point of peak infectivity (59 ). Data from serologic surveys of many types of
health-care workers have not indicated an increased prevalence of HAV infection in
these groups compared with that in control populations (60–62 ).
Institutions for Persons Who Have Developmental Disabilities
Historically, HAV infection was highly endemic in institutions for persons who have
developmental disabilities (63 ). As fewer children have been institutionalized
and conditions within institutions have improved, the incidence and prevalence of
HAV infection have decreased, although sporadic outbreaks can occur in these
settings (51 ).
Schools
In the United States, the occurrence of cases of hepatitis A within elementary or
secondary schools usually reflects disease acquisition within the community. Child-to-
child disease transmission within the school setting is uncommon; thus, if multiple
cases occur among children at a school, the possibility of a common source of infec-
tion should be investigated (51 ).
Workers Exposed to Sewage
Data from serologic studies among Scandinavian and English workers who had
been exposed to sewage indicate a possible elevated risk for HAV infection; however,
in these studies, the data were not controlled for other risk factors (e.g., socioeco-
nomic status) (64,65 ). In the United States, no work-related cases of HAV transmission
have been reported among workers exposed to sewage, and serologic data are not
available.
Other Settings
Waterborne outbreaks of hepatitis A are infrequent. Most outbreaks are associated
with sewage-contaminated water or inadequately treated water (66,67 ).
Surveillance for Hepatitis A
Hepatitis A is a reportable disease in all states. The goals of hepatitis A surveillance
at the national, state, and local levels include a) monitoring disease incidence by
identifying acute, symptomatic infections in all age groups; b) determining the
epidemiologic characteristics of infected persons, including the source of infection;
c) identifying contacts of case-patients who might require postexposure prophylaxis;
Vol. 45 / No. RR-15 MMWR 9
d) detecting outbreaks; e) determining the effectiveness of hepatitis A vaccination;
and f) determining missed opportunities for vaccination. 
Cases of hepatitis A should be reported to local or state health departments (ac-
cording to specific state requirements) so that appropriate control measures can be
implemented, if indicated. Cases meeting specified criteria are reported by state
health departments to CDC (68 ). Hepatitis A surveillance must be maintained at the
local level so that the various immunization strategies recommended in this report
can be implemented and their outcome at the local, state, and national levels can be
assessed.
RATIONALE FOR PREVENTION OF HEPATITIS A THROUGH
ACTIVE IMMUNIZATION
In the United States during the past several decades, a decline in the overall inci-
dence of hepatitis A has occurred primarily as a result of better hygienic and sanitary
conditions (e.g., improved water supplies, sewage disposal, and food sanitation and
less crowded living conditions). Although passive immunization with IG has been
available for several decades, its effect on lowering the incidence of hepatitis A has
been limited. High rates of disease among many segments of the U.S. population and
the continued occurrence of extensive communitywide outbreaks indicate that hepa-
titis A remains a major public health problem.
The availability of hepatitis A vaccine provides an opportunity to substantially
lower disease incidence and eventually eradicate infection. This reduction in disease
incidence will be achieved by producing high levels of immunity in persons in age
groups that have the highest rates of HAV infection and that serve as a reservoir of
infection (26 ). Producing a highly immune population decreases the incidence of
hepatitis A and presumably decreases virus circulation by preventing fecal shedding
of HAV. Populations are highly immune following an epidemic in communities that
have high rates of hepatitis A or following vaccination in such communities (29 ).
Hepatitis A immunization is likely to substantially lower disease incidence because
HAV does not produce a chronic infection, and humans are the only natural reservoir
of the virus.
Because of their critical role in HAV transmission, children should be a primary fo-
cus of immunization strategies to lower disease incidence. Thus, the most effective
means of achieving control of HAV infection would be to include routine hepatitis A
vaccination in the childhood vaccination schedule. However, the lack of data available
for determining the appropriate dose and timing of vaccination in the first or second
year of life presents a barrier to the implementation of this strategy. Combination vac-
cines that include inactivated HAV would minimize the number of injections
administered to children.
Until hepatitis A vaccine is licensed for use among children <2 years of age, the
interim strategy to prevent and control hepatitis A should focus on preexposure
vaccination of the following persons: a) persons at increased risk for HAV infection or
its consequences (e.g., travelers and persons who have chronic liver disease); b) chil-
dren living in communities that have high rates of hepatitis A to help prevent recurrent
epidemics; and, if indicated, c) children and young adults in communities that have in-
termediate rates of hepatitis A to help control ongoing and prevent future epidemics.
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In addition, contacts of case-patients should be administered postexposure prophy-
laxis (i.e., IG or, when appropriate, IG and hepatitis A vaccine).
Vaccination of persons in groups at increased risk for HAV infection (e.g., travelers)
will likely have little effect on national disease rates because most cases do not occur
among persons in these groups. Vaccination of persons in communities with high and
intermediate rates of disease might have an impact on national disease incidence.
However, a substantial reduction in the incidence of disease cannot be expected until
hepatitis A vaccine is included in the routine childhood immunization schedule and
successive cohorts of children are vaccinated.
PROPHYLAXIS AGAINST HEPATITIS A VIRUS INFECTION
Immune Globulin
IG is a sterile preparation of concentrated antibodies (immunoglobulins) made
from pooled human plasma processed by cold ethanol fractionation (69 ). In the
United States, only plasma that has tested negative for a) hepatitis B surface antigen
(HBsAg), b) antibody to human immunodeficiency virus (HIV), and c) antibody to
hepatitis C virus (HCV) is used to manufacture IG. Cold ethanol fractionation can elimi-
nate and inactivate HIV (70 ). Furthermore, no transmission of hepatitis B virus, HIV,
HCV, or other viruses has been reported from the intramuscular (IM) administration of
IG (71 ). Anti-HAV titers differ between IG lots, and slightly lower titers have been
observed in recent years, probably because of the decreasing prevalence of HAV infec-
tion among plasma donors (72 ). However, no clinical or epidemiologic evidence of
decreased protection has been observed. 
IG provides protection against hepatitis A through passive transfer of antibody. The
levels of anti-HAV achieved following IM administration of IG are below the level of
detection of most commercially available diagnostic tests (73 ). When administered
for preexposure prophylaxis, a dose of 0.02 mL/kg IM confers protection for
<3 months, and a dose of 0.06 mL/kg IM confers protection for ≤5 months (Table 3).
When administered within 2 weeks following an exposure to HAV, IG is >85% effective
in preventing hepatitis A (74–76 ). Efficacy is greatest when IG is administered early in
the HAV incubation period; when administered later in the incubation period, IG often
only attenuates the clinical expression of HAV infection (74 ).
For administration of IG, an appropriate muscle mass (i.e., the deltoid or gluteal
muscle) should be chosen into which a large volume of IG can be injected by using a
needle length appropriate for the person’s age and size (77 ). If a gluteal muscle is
TABLE 3. Recommended doses of immune globulin (IG) for hepatitis A preexposure
and postexposure prophylaxis
Setting Duration of Coverage IG Dose*
Preexposure Short-term (1–2 mos) 0.02 mL/kg
Long-term (3–5 mos) 0.06 mL/kg† 
Postexposure — 0.02 mL/kg
*IG should be administered by intramuscular injection into either the deltoid or gluteal muscle.
For children <24 months of age, IG can be administered in the anterolateral thigh muscle.
†Repeat every 5 months if continued exposure to HAV occurs.
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used, the central region of the buttock should be avoided: only the upper outer quad-
rant should be used, and the needle should be directed anteriorly to minimize the
possibility of injury to the sciatic nerve (77 ).
Serious adverse events from IG are rare. Anaphylaxis has been reported after
repeated administration to persons who have known IgA deficiency; thus, IG should
not be administered to these persons (78 ). Pregnancy or lactation is not a contraindi-
cation to IG administration.
IG does not interfere with the immune response to oral poliovirus vaccine or yellow
fever vaccine, or, in general, to inactivated vaccines. However, IG can interfere with the
response to live, attenuated vaccines (e.g., measles, mumps, rubella, and varicella)
when vaccines are administered either individually or as combination vaccines.
Administration of these vaccines should be delayed for at least 5 months after admini-
stration of IG for hepatitis A prophylaxis. IG should not be administered within
2 weeks after the administration of live, attenuated vaccines (or within 3 weeks after
varicella vaccine) unless the benefits of IG administration exceed the benefits of vac-
cination (77 ). If IG is administered within 2 weeks after administration of these
vaccines (or within 3 weeks after administration of varicella vaccine), the person
should be revaccinated, but not sooner than 5 months after the administration of
IG (77 ).
Hepatitis A Vaccine
Several inactivated and attenuated hepatitis A vaccines have been developed and
evaluated in human clinical trials and in primate models of HAV infection (79 ); how-
ever, only inactivated vaccines have been evaluated for efficacy in controlled clinical
trials (3,4 ). The vaccines currently licensed in the United States are HAVRIX® (manu-
factured by SmithKline Beecham Biologicals) and VAQTA® (manufactured by Merck &
Company, Inc). Both are inactivated vaccines.
Preparation
Inactivated hepatitis A vaccine is prepared by methods similar to those used for
inactivated poliovirus vaccine (80,81 ). Cell-culture–adapted virus is propagated in
human fibroblasts, purified from cell lysates by ultrafiltration and exclusion gel chro-
matography or other methods, formalin inactivated, adsorbed to an aluminum
hydroxide adjuvant, and prepared with 2-phenoxyethanol (for HAVRIX®) as a preserv-
ative; VAQTA® is formulated without a preservative. For HAVRIX,® the antigen content
of the final aqueous preparation is determined by reactivity in a quantitative immuno-
assay for HAV antigen, and final vaccine potency (per dose) is expressed as enzyme-
linked immunosorbent assay (ELISA) units (EL.U.). For VAQTA,® the antigen content is
expressed as units (U) of hepatitis A antigen.
Vaccine Storage and Shipment
Hepatitis A vaccine should be stored and shipped at temperatures ranging from
35.6 F (2 C) to 46.4 F (8 C) and should not be frozen. However, the reactogenicity and
immunogenicity of HAVRIX® and VAQTA® after storage at 98.6 F (37 C) for 1 week do
not differ from those of vaccines stored at the recommended temperature (82 ; Merck
& Company, Inc., unpublished data).
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Route of Administration, Vaccination Schedule, and Dosage
The vaccine should be administered intramuscularly into the deltoid muscle. A
needle length appropriate for the vaccinee’s age and size should be used (77 ).
HAVRIX® is currently licensed in three formulations, and the formulation and
number of doses differ according to the vaccinee’s age: for persons 2–18 years of age,
360 EL.U. per dose in a three-dose schedule and 720 EL.U. per dose in a two-dose
schedule; for persons >18 years of age, 1,440 EL.U. per dose in a two-dose schedule
(Table 4). VAQTA® is licensed in two formulations, and the formulation and number of
doses differ according to the person’s age: for persons 2–17 years of age, 25 U in a
two-dose schedule; for persons >17 years of age, 50 U per dose in a two-dose sched-
ule (Table 5).
Vaccine Performance
Detection of anti-HAV after vaccination. Concentrations of antibody achieved after
passive transfer by IG or active induction by vaccination are 10-100–fold lower than
those produced after natural infection and are often below the detection level of
standard, commercially available assays (73 ). To measure lower levels of antibody,
more sensitive immunoassays have been developed that correlate more closely with
neutralizing antibody assays (73 ). The anti-HAV immunoassays commercially avail-
able in the United States can be modified to detect lower concentrations of antibody;
however, the modified assays have not been reviewed by the U.S. Food and Drug
Administration and are not approved for any clinical indication. Anti-HAV concentra-
tions are measured in comparison with a World Health Organization reference
immunoglobulin reagent and are expressed as milli-International Units per milliliter
(mIU/mL). The lower limits of detection are approximately 100 mIU/mL by unmodified,
commercially available assays and 10-12 mIU/mL by modified assays. Thus, a positive
TABLE 4. Recommended dosages of HAVRIX*
Vaccinee’s age
(yrs) Dose (EL.U.)† Volume (mL) No. doses Schedule (mos)§
2–18   720 0.5 2 0, 6–12
 >18 1,440 1.0 2 0, 6–12
*Hepatitis A vaccine, inactivated, SmithKline Beecham Biologicals.
†ELISA units.
§0 months represents timing of the initial dose; subsequent numbers represent months after
the initial dose.
TABLE 5. Recommended dosages of VAQTA*
Vaccinee’s age
(yrs) Dose (U)† Volume (mL) No. doses Schedule (mos)§
2–17 25 0.5 2 0, 6–18
 >17 50 1.0 2    0, 6
*Hepatitis A vaccine, inactivated, Merck & Company, Inc.
†Units.
§0 months represents timing of the initial dose; subsequent numbers represent months after
the initial dose.
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anti-HAV result by a standard assay indicates protection. However, after vaccination,
persons who are anti-HAV negative by standard assays might still have protective lev-
els of antibody.
The absolute lower limit of antibody required to prevent HAV infection has not been
defined. In vitro studies using cell-culture–derived virus indicate that low levels of
antibody (e.g., <20 mIU/mL) can be neutralizing (83 ). Clinical studies have yielded few
data from which a minimum protective antibody level can be derived because
vaccine-induced levels of antibody have been high and few infections have been de-
tected among vaccinated persons. Experimental studies in chimpanzees indicate that
low levels of passively transferred antibody (<10 mIU/mL) obtained from immunized
persons do not protect against infection but do prevent clinical hepatitis and virus
shedding (84 ). To define a protective antibody response, most clinical studies
conducted with HAVRIX® have been based on levels >20 mIU/mL as measured with a
modified enzyme immunoassay, and studies conducted with VAQTA® have been
based on levels >10 mIU/mL as measured with a modified radioimmunoassay (85,86 ).
Immunogenicity in adults. HAVRIX® is highly immunogenic in persons ≥18 years of
age if two doses of 1,440 EL.U. are administered on a 0- and 6-to-12–month schedule
(86 ). Anti-HAV levels >20 mIU/mL developed in 88% (range: 80%–98%) of adults
15 days after the first dose and in 99%–100% of adults at 1 month. Among a sample of
vaccinees, 54%–62% of persons were positive for neutralizing antibody 14 days after
the first dose, and 94%–100% of persons were positive at 1 month (86 ; SmithKline
Beecham Biologicals, unpublished data). After the second dose, all persons had pro-
tective levels of antibody (>20 mIU/mL) with a high geometric mean titer (GMT)
(Table 6), and all were positive for neutralizing antibody (SmithKline Beecham Biologi-
cals, unpublished data).
VAQTA® provides similar immunogenicity when administered to adults ≥18 years
of age (Table 7). Among vaccinated persons who received 50 U at 0 and 6 months, 95%
had protective anti-HAV levels at 1 month, and 100% had protective levels at 7 months.
The GMT, measured by using a modified hepatitis A antibody (HAVAB) assay, was
37 mIU/mL at 1 month and 5,059 mIU/mL at 7 months (87 ).
Immunogenicity in children and adolescents. Of persons 1–17 years of age who
were administered three doses of 360 EL.U. of HAVRIX® on a 0-, 1-, and 6-month
schedule, 95% developed protective levels of anti-HAV 1 month after the first dose
(86,88–90 ). One month after the second dose, all persons had protective levels of an-
tibody that persisted until administration of the third dose at 6 months. One month
following the third dose, the GMT increased approximately tenfold and persisted at
high levels 6 months later (Table 6).
Among children and adolescents 2–18 years of age who were administered two
doses of HAVRIX® (720 EL.U. per dose at 0- and 6-month intervals), 99% had protective
levels of antibody 1 month after receiving the first dose (Table 6). Similar 1-month
results were obtained for adolescents who had been administered two doses of
HAVRIX® (1,440 EL.U. per dose).
When administered to persons 2–17 years of age in a variety of two-dose schedules
(25 U per dose), VAQTA® was highly immunogenic. From 97% to 100% of children had
protective levels 1 month after the first dose, and 100% had protective levels 1 month
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TABLE 6. Summary of selected studies on the immunogenicity of HAVRIX, by age group*
Age Group (yrs)
Dose
(EL.U.)†
Schedule
(mos)§
Studies
(No.)
Persons
(No.)
% Seroconversion (GMT)¶ by time after receiving
first vaccine dose**
15 days 1 mo 3 mos 6 mos 7 mos 15 mos
Infants††   360 2, 4, 6 1  38   100
(  794)
100
(231)
Children and adolescents
(ages 1–17 yrs)
  360 0, 1, 6 5 524  95
(179)
100
(433)
100
(308)
 100
(3,831)
  100
(1,069)
Children and adolescents
(ages 2–18 yrs)
  720   0, 6 5 336  93
(243)
 99
(253)
  100
(2,576)
Adolescents
(ages 11–17 yrs)
1,440   0, 6 1  91  98
(294)
  100
(5,406)
Adults 1,440   0, 6 3 450  88
(293)
 99
(466)
  100
(4,383)
 *Source: SmithKline Beecham Biologicals.
† ELISA units.
§ 0 months represents timing of the initial dose and subsequent numbers represent months after the initial dose, except for infants,
for whom months indicate age at time of vaccination.
¶ Geometric mean titer in milli-International Units per milliliter.
**GMT results are shown only for those time points at which data are available.
†† Without passively acquired maternal antibody.
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TABLE 7. Summary of selected studies on the immunogenicity of VAQTA, by age group*
Age group (yrs) Dose†
Schedule
(mos)§
% Seroconversion (GMT¶) by time after receiving first vaccine dose 
Persons
(No.) 1 mo 6 mos 7 mos 12 mos 13 mos 18 mos 19 mos
Children and adolescents
(age 2–17 yrs)
25 0, 6   132  98
(37)
 97
( 69)
  100
(6,755)
Children and adolescents
(age 2–17 yrs)
25 0,12   133 100
(46)
100
( 57)
95
(52)
   100
(12,799)
Children and adolescents
(age 2–17 yrs)
25 0,18   130 100
(48)
100
(252)
89
(39)
  100
(9,792)
Adults 50 0, 6 1,436  95
(37)
 98
(210)
  100
(5,059)
*Source: Merck & Company, Inc.
†Units.
§0 months represents timing of the initial dose and subsequent numbers represent months after the initial dose, except for infants, for
whom months indicate age at time of vaccination.
¶Geometric mean titer in milli-International Units per milliliter.
after administration of a second dose at 6, 12, or 18 months, with substantial increases
in GMT after administration of the second dose (Table 7) (87 ).
Immunogenicity in infants. Few data are available regarding the use of hepatitis A
vaccine in children <2 years of age. Results from one study indicated that among
infants without passively acquired maternal anti-HAV who had been administered
hepatitis A vaccine (360 EL.U. per dose) at 2, 4, and 6 months of age, 100% of the
infants had protective antibody levels with a GMT of 794 mIU/mL 1 month following
the third dose (91 ) (Table 6). Infants with passively transferred maternal anti-HAV had
a reduced anti-HAV GMT after vaccination (see Factors Associated with Reduced
Immunogenicity).
IgM anti-HAV after vaccination. Hepatitis A vaccination rarely induces IgM anti-
HAV that is detectable by standard assays. In one study, three of approximately
311 adult vaccine recipients transiently developed IgM anti-HAV 1 month after com-
pleting vaccination with 720 EL.U. of HAVRIX® on a 0-, 1-, and 6-month schedule (92 ).
In another study, none of 158 children studied had detectable IgM anti-HAV 1 month
after receiving two doses of HAVRIX® (360 EL.U. per dose) (SmithKline Beecham Bi-
ologicals, unpublished data). IgM anti-HAV was detected in three of 15 persons at
2–3 weeks after having been administered VAQTA® (93 ).
Efficacy. The efficacy of HAVRIX® was evaluated in a double-blind, placebo-
controlled, randomized clinical trial conducted in Thailand among approximately
40,000 children 1–16 years of age living in villages that had high rates of hepatitis A
(4 ). After two doses of vaccine (360 EL.U. per dose) administered 1 month apart, the
efficacy of vaccine in protecting against clinical hepatitis A was 94% (95% confidence
interval=79%–99%). A double-blind, placebo-controlled, randomized clinical trial using
VAQTA® was conducted among approximately 1,000 children 2–16 years of age living
in a New York community that had a high rate of hepatitis A. The protective efficacy
against clinical hepatitis A was 100% after administration of one dose (25 U) of
vaccine (3 ).
Studies of chimpanzees indicate that hepatitis A vaccine can prevent HAV infection
if administered shortly after exposure (94 ). Because the incubation period of hepati-
tis A can be ≤50 days, the fact that no cases of hepatitis A occurred in vaccine
recipients beginning 19 days after vaccination indicates a possible postexposure ef-
fect (3 ). A study comparing the postexposure efficacy of hepatitis A vaccine versus IG
has not been done.
Effectiveness in outbreak settings. Several studies have examined the effective-
ness of hepatitis A vaccine in controlling outbreaks in communities that have high
rates of hepatitis A. Specifically, vaccination using VAQTA® of children 2–16 years of
age during the clinical trial evaluating vaccine efficacy resulted in a substantial de-
crease in community hepatitis A rates (3 ). In addition, in several Alaskan villages in
which hepatitis A outbreaks were occurring, vaccination of susceptible persons
<30 years of age with one dose of HAVRIX® (720 EL.U.) resulted in a rapid decrease in
the number of cases (95 ). Both studies were carried out in small, well-defined
communities in which an estimated 70% or more of the susceptible persons were
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vaccinated. Cost analyses have indicated that vaccination in communities that have
high rates of hepatitis A can be cost-saving (96 ). Hepatitis A vaccine has been used in
several communities that had intermediate rates of hepatitis A and were experiencing
outbreaks. In Butte County, California, hepatitis A cases decreased concurrently with
the implementation of a program in which approximately 37% of children 2–12 years
of age were administered one dose of VAQTA® (97 ). In Memphis, Tennessee, follow-
ing a targeted vaccination program in which one dose of HAVRIX® (360 EL.U.) was
administered to 52% of eligible children 2–9 years of age, hepatitis A rates decreased
in this target population (98 ). In two villages in Slovakia, a communitywide outbreak
ended 2 months after approximately two thirds of school-age children were vacci-
nated with two doses of HAVRIX® (99 ). Further study is needed to determine the
effectiveness of this strategy, the feasibility of implementation, and level of vaccina-
tion coverage required to interrupt disease transmission.
Long-term protection. Data concerning the long-term persistence of antibody and
of immune memory are limited because the currently available vaccines have been
under evaluation for only 4–5 years. Among adults who received three doses of
HAVRIX® (720 EL.U. per dose at 0-, 1-, and 6-month intervals), 100% of those persons
had anti-HAV levels >20 mIU/mL 48 months after the initial dose, although antibody
concentrations had decreased by approximately 50% (P. Van Damme, University of
Antwerp [Belgium], unpublished data). Data regarding persons who were adminis-
tered VAQTA® and who were monitored for 36 months also demonstrated a decrease
in titer; however, protective levels of anti-HAV were still observed in 100% of these
persons (100 ). Estimates of antibody persistence derived from kinetic models of anti-
body decline indicate that protective levels of anti-HAV could be present for ≥20 years
(100,101 ). Whether other mechanisms (e.g., cellular memory) also contribute to long-
term protection is unknown. The long-term protective efficacy of hepatitis A vaccine
needs to be determined in ongoing studies to detect clinical illness among vaccinees
and in future postmarketing surveillance studies before recommendations can be
made concerning the possible need for booster doses.
Factors associated with reduced immunogenicity. In one study, the percentage of
adults who were administered IG concurrently with the first dose of hepatitis A
vaccine and who had protective levels of antibody was similar to the percentage of
adults who had protective levels and who had been administered hepatitis A vaccine
alone; however, their GMTs were substantially lower 1 month after being adminis-
tered three doses of HAVRIX® (720 EL.U. per dose) than GMTs of adults who had been
administered hepatitis A vaccine alone (GMT 2,488 MIU/mL versus 3,614 mIU/mL, re-
spectively) (102 ). In both groups, the antibody levels were at least 100-fold higher
than levels considered to be protective. A similar effect occurred with concurrent ad-
ministration of IG and VAQTA® (Merck & Company, Inc., unpublished data). Therefore,
the reduced immunogenicity of hepatitis A vaccine that occurs with concurrent ad-
ministration of IG is not expected to be clinically significant.
Reduced immunogenicity also was observed in infants who had passively acquired
antibody because of prior maternal HAV infection (91 ). Infants who were adminis-
tered HAVRIX® (360 EL.U. per dose) at 2, 4, and 6 months of age and whose mothers
were anti-HAV positive had antibody levels at 15 months of age that were one third the
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levels in infants who had been administered HAVRIX® on the same schedule but
whose mothers were anti-HAV negative (GMT 84 mIU/mL versus 231 mIU/mL, respec-
tively). However, 93% and 100% of infants in each group, respectively, had anti-HAV
levels >20 mIU/mL.
In one study, the proportion of persons >40 years of age who had protective anti-
body levels after three doses of HAVRIX® (720 EL.U. per dose) was similar to that of
persons ≤40 years of age, although the final GMTs were approximately 50% lower
(SmithKline Beecham Biologicals, unpublished data). Data from one study of HIV-
infected persons vaccinated with three doses of 720 EL.U. of HAVRIX® indicate that
both the proportion of those who developed protective antibody levels and their GMTs
were lower than those in anti-HIV negative persons (77% versus 100%; 636 mIU/mL
versus 1,687 mIU/mL, respectively) (103 ).
Other factors associated with decreased immunogenicity to other vaccines (e.g.,
smoking) have not been evaluated for hepatitis A vaccine. No data are available per-
taining to response rates to revaccination among persons who do not respond to the
primary vaccination series.
Simultaneous administration with other vaccines. Limited data from studies con-
ducted among adults indicate that simultaneous administration of hepatitis A vaccine
with diphtheria, poliovirus (oral and inactivated), tetanus, oral typhoid, cholera, Japa-
nese encephalitis, rabies, or yellow fever vaccine does not decrease the immune
response to either vaccine or increase the frequency of reported adverse events (104 ;
SmithKline Beecham Biologicals, unpublished data). Studies indicate that hepatitis B
vaccine can be administered simultaneously with either HAVRIX® or VAQTA® without
either affecting immunogenicity or increasing the frequency of adverse events (105 ).
Several studies are being conducted among infants to evaluate the effect of simulta-
neous administration of hepatitis A, diphtheria-tetanus-pertussis (DTP), and oral
poliovirus vaccines on the immunogenicity and reactogenicity of these vaccines.
Side Effects and Adverse Events
Data concerning adverse events are derived from prelicensure clinical studies
worldwide and from reports following vaccine licensure of HAVRIX® in Europe and
Asia. Approximately 50,000 persons have been administered HAVRIX® in clinical stud-
ies. No serious adverse events have been attributed definitively to hepatitis A vaccine.
Among adults, the most frequently reported side effects occurring within 3 days after
the 1,440 EL.U. dose were soreness at the injection site (56%), headache (14%), and
malaise (7%); the incidence of side effects generally has been similar to that of hepa-
titis B vaccine. In clinical studies among children, the most frequently reported side
effects were soreness at the injection site (15%), feeding problems (8%), headache
(4%), and injection-site induration (4%). No serious adverse events were reported for
approximately 40,000 children who were administered the 360 EL.U. dose of hepati-
tis A vaccine in the protective efficacy study (4 ).
Approximately 9,200 persons have been administered VAQTA® in clinical studies.
No serious adverse events were reported among participants in the clinical studies.
Among adults, the most frequent side effects that occurred within 5 days following
vaccination include tenderness (53%), pain (51%), and warmth (17.3%) at the injection
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site (53%) and headache (16.1%). Among children, the most common side effects re-
ported were pain (19%), tenderness (17%), and warmth (9%) at the injection site.
An estimated 1.3 million persons have been vaccinated with HAVRIX® since it was
licensed in Europe and Asia. Postlicensure reports of serious adverse events, without
regard to causality, received by the vaccine manufacturer have included anaphylaxis,
Guillain-Barré syndrome, brachial plexus neuropathy, transverse myelitis, multiple
sclerosis, encephalopathy, and erythema multiforme (SmithKline Beecham Biologi-
cals, unpublished data). Most of these events have occurred among adults, and
approximately one third have occurred among persons receiving other vaccines con-
currently. For serious adverse events for which background incidence data are known
(e.g., Guillain-Barré syndrome and brachial plexus neuropathy), the rates for vaccine
recipients are not higher than would be expected for an unvaccinated population
(CDC, unpublished data). In Europe, the ratio of reported adverse events to the num-
ber of doses distributed is similar for the manufacturer’s hepatitis A and hepatitis B
vaccines (SmithKline Beecham Biologicals, unpublished data).
Because VAQTA® was recently licensed, postmarketing data are limited. An esti-
mated 20,000 persons have been administered VAQTA® since it was licensed in the
United States and Germany, and no serious adverse events have been reported
(Merck & Company, Inc., unpublished data).
Any adverse event suspected to be associated with hepatitis A vaccination should
be reported to the Vaccine Adverse Events Reporting System (VAERS). VAERS forms
can be obtained by calling 1-800-822-7967.
Contraindications and Precautions
Hepatitis A vaccine should not be administered to persons with a history of
hypersensitivity reactions to alum or, in the case of HAVRIX®, to the preservative
2-phenoxyethanol.
The safety of hepatitis A vaccination during pregnancy has not been determined;
however, because hepatitis A vaccine is produced from inactivated HAV, the theoreti-
cal risk to the developing fetus is expected to be low. The risk associated with
vaccination should be weighed against the risk for hepatitis A in women who may be
at high risk for exposure to HAV. Because hepatitis A vaccine is inactivated, no special
precautions need to be taken when vaccinating immunocompromised persons.
Prevaccination Serologic Testing for Susceptibility
HAV infection produces lifelong immunity to hepatitis A and, presumably, to HAV
infection. Vaccination of a person who is immune because of prior infection does not
increase the risk for adverse events. In populations that have expected high rates of
prior HAV infection, prevaccination testing may be considered to reduce costs by not
vaccinating persons who have prior immunity. Testing of children is not indicated be-
cause of their expected low prevalence of infection. For adults, the decision to test
should be based on a) the expected prevalence of immunity; b) the cost of vaccination
compared with the cost of serologic testing (including the cost of an additional visit);
and c) the likelihood that testing will not interfere with initiating vaccination. For ex-
ample, if the cost of screening (including laboratory and office visits) is one third the
cost of the vaccine series, then screening potential recipients in populations where the
prevalence of infection is likely to be >33% should be cost effective (106 ).
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Persons for whom prevaccination testing will likely be most cost effective include
adults who were either born in or lived for extensive periods in geographic areas that
have a high endemicity of HAV infection (Figure 3); older adolescents and adults in
certain population groups (i.e., American Indians, Alaskan Natives, and Hispanics);
and adults in certain groups that have a high prevalence of infection (e.g., men who
have sex with men). In addition, among older adults, the prevalence may be high
enough to warrant prevaccination testing. For example, the anti-HAV prevalence
among persons >40 years of age, determined by NHANES-III testing, is generally
>33% (regardless of race/ethnicity or income level). Thus, if the cost of screening is
one third the cost of the vaccination series, prevaccination testing of any person
>40 years of age would likely be cost effective. Commercially available tests for total
anti-HAV should be used for prevaccination testing. 
Postvaccination Testing for Serologic Response
Postvaccination testing is not indicated because of the high rate of vaccine re-
sponse among adults and children. Testing methods that have the sensitivity to detect
low anti-HAV concentrations after vaccination are not approved for routine diagnostic
use in the United States.
RECOMMENDATIONS FOR USE OF HEPATITIS A VACCINE
AND IMMUNE GLOBULIN
Preexposure Protection Against Hepatitis A Virus Infection
Hepatitis A vaccination provides preexposure protection from HAV infection in chil-
dren and adults. Hepatitis A vaccination is recommended for persons who are at
increased risk for infection and for any person wishing to obtain immunity.
Populations at Increased Risk for HAV Infection or the Adverse
Consequences of Infection
• Persons traveling to or working in countries that have high or intermediate en-
demicity of infection. All susceptible persons traveling to or working in countries
that have high or intermediate HAV endemicity (Figure 3) should be vaccinated or
receive IG before departure (Tables 3 and 4). Hepatitis A vaccination at the age-
appropriate dose is preferred (Table 4) for children, adolescents, and adults who
plan frequent travel or who reside for long periods in a high-risk area. IG is rec-
ommended for travelers <2 years of age because the vaccine is currently not
licensed for use in this age group. Prevaccination testing should be considered
for older travelers or for younger persons in certain population groups (see Pre-
vaccination Serologic Testing for Susceptibility).
Travelers to North America (except Mexico and Central America), western
Europe, Japan, Australia, or New Zealand are at no greater risk for infection than
in the United States. Data are not available regarding the risk for hepatitis A for
persons traveling to developed areas of the Caribbean, although vaccine or IG
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should be considered if travel to areas that have questionable sanitation is antici-
pated.
Travelers who are administered vaccine should receive the first vaccine dose at
least 4 weeks before travel. Persons can be assumed to be protected by 4 weeks
after receiving the first vaccine dose, although a second dose 6–12 months later
is necessary for long-term protection. Because protection may not be complete
until 4 weeks after vaccination, persons traveling to a high-risk area <4 weeks
after the initial dose also should be administered IG (0.02 mL/kg), but at a different
anatomic injection site.
Travelers who are allergic to a vaccine component or who elect not to receive
vaccine should receive a single dose of IG (0.02 mL/kg), which provides effective
protection against hepatitis A for up to 3 months (Table 3). Travelers whose travel
period exceeds 2 months should be administered IG at 0.06 mL/kg; administration
must be repeated if the travel period exceeds 5 months (Table 3).
• Children in communities that have high rates of hepatitis A and periodic hepati-
tis A outbreaks. Children living in communities that have high rates of hepatitis A
(Table 2) should be routinely vaccinated beginning at ≥2 years of age. In addition,
to effectively prevent epidemics of hepatitis A in these communities, vaccination
of previously unvaccinated older children is recommended within 5 years of in-
itiation of routine childhood vaccination programs. Although rates differ among
areas, available data indicate that a reasonable cutoff age in many areas is 10-
15 years of age because older persons often are already immune and vaccination
of younger children will indirectly protect older persons who may be susceptible.
Vaccination of children before they enter school should receive highest priority,
followed by vaccination of older children who have not been vaccinated. Pre-
vaccination serologic testing is not indicated for vaccination of previously unvac-
cinated children in this setting.
• Men who have sex with men. Sexually active men who have sex with men (both
adolescents and adults) should be vaccinated. Prevaccination testing is not indi-
cated for the vaccination of adolescents in this group, yet may be warranted for
adults, especially those >40 years of age.
• Illegal-drug users. Vaccination is recommended for injecting and noninjecting
illegal-drug users if local epidemiologic and surveillance data indicate current or
past outbreaks among persons with such risk behaviors. Prevaccination testing is
not indicated for the vaccination of adolescent illegal-drug users but may be war-
ranted for adults, especially those >40 years of age, who practice such behaviors.
• Persons who have occupational risk for infection. Persons who work with HAV-
infected primates or with HAV in a research laboratory setting should be vacci-
nated. No other groups have been shown to be at increased risk for HAV infection
because of occupational exposure.
• Persons who have chronic liver disease. Susceptible persons who have chronic
liver disease should be vaccinated. Persons who are either awaiting or have re-
ceived liver transplants also should be vaccinated.
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• Persons who have clotting-factor disorders. Susceptible persons who are
administered clotting-factor concentrates, especially solvent-detergent–treated
preparations, should be administered hepatitis A vaccine.
• Other groups. Persons who work as food handlers can contract hepatitis A and
potentially transmit HAV to others. To decrease the frequency of evaluations of
food handlers with hepatitis A and the need for postexposure prophylaxis of pa-
trons, consideration may be given to vaccination of employees who work in
areas where state and local health authorities or private employers determine
that such vaccination is cost effective.
Hepatitis A Vaccination in Outbreak Settings
• Outbreaks in communities that have high rates of hepatitis A. Routine vaccina-
tion of children 2 years of age and accelerated vaccination of older children who
have not been previously vaccinated should be implemented to control an ongo-
ing outbreak. The upper age for vaccination of older, previously unvaccinated
children should be determined by using age-specific rates of hepatitis A (or sero-
prevalence data, if available). In communities that have begun a vaccination
program (i.e., routine vaccination of children 2 years of age and vaccination of
older children who have not been previously vaccinated), the vaccination compo-
nent directed toward older children who have not been previously vaccinated
should be accelerated so that at least 70% coverage is achieved as quickly as
possible.
• Outbreaks in communities that have intermediate rates of hepatitis A. Hepati-
tis A vaccination of children or adolescents may have the potential to control
hepatitis A outbreaks in these communities (Table 2). These communities often
are located in large cities or counties; thus, widespread vaccination may not be
feasible. Targeting vaccination to subpopulations or groups that have the highest
rates of disease may be more feasible; however, the effectiveness of using
vaccine in these settings and under these conditions has not been determined.
To determine candidate groups for vaccination, local surveillance and epidem-
iologic data should be used to define populations (e.g., age groups or risk groups)
or areas within the community (e.g., census tracts) that have the highest rates of
disease. Factors to consider in deciding whether to vaccinate persons in a certain
group include a) the feasibility of rapidly vaccinating the target populations of
children, adolescents, or young adults; b) program cost; and c) the ability to sus-
tain ongoing vaccination of young children to maintain high levels of immunity
and prevent future epidemics.
In some communities, day care centers play a role in sustaining communitywide
outbreaks. In this situation, consideration should be given to adding hepatitis A
vaccine to the immunoprophylaxis regimen for children and staff in the involved
center or centers (see Postexposure Prophylaxis with Immune Globulin) and, pos-
sibly, vaccinating children in day care centers where cases of hepatitis A have not
been detected.
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Because experience when using hepatitis A vaccine to control hepatitis A in com-
munities that have intermediate rates of hepatitis A is limited, evaluation of the
effectiveness of vaccination should be an essential element of programs in these
settings.
• Outbreaks in other settings. The frequency of outbreaks in day care centers,
hospitals, institutions (e.g., institutions for the developmentally disabled
and prisons), and schools is not high enough to warrant routine hepatitis A vac-
cination of persons in these settings. When outbreaks are recognized in day
care centers, aggressive use of IG is effective in limiting transmission to employ-
ees and families of attendees (see Postexposure Prophylaxis with Immune
Globulin). When outbreaks occur in hospitals, institutions, and schools, use of IG
in persons in close contact with infected patients or students who have hepatitis
A is recommended (see Postexposure Prophylaxis with Immune Globulin). The
role of hepatitis A vaccine in controlling outbreaks in these settings has not been
investigated.
Postexposure Prophylaxis with Immune Globulin
Persons who have been recently exposed to HAV and who have not previously
been administered hepatitis A vaccine should be administered a single IM dose of IG
(0.02 mL/kg) as soon as possible, but not >2 weeks after exposure. Persons who have
been administered one dose of hepatitis A vaccine at least 1 month before exposure
to HAV do not need IG.
Because hepatitis A cannot be reliably diagnosed on clinical presentation alone,
serologic confirmation of HAV infection in index patients by IgM anti-HAV testing is
recommended before postexposure treatment of contacts. Screening of contacts for
immunity before giving IG is not recommended because screening is more costly than
IG and would delay its administration.
IG should be administered to previously unvaccinated persons in the following
situations. If hepatitis A vaccine is recommended for a person being given IG, it may
be administered simultaneously with IG at a separate anatomic injection site. 
• Close personal contact. IG should be administered to all household and sexual
contacts of persons who have serologically confirmed hepatitis A.
• Day care centers. IG should be administered to all staff and attendees of day care
centers or homes if a) one or more cases of hepatitis A are recognized in children
or employees or b) cases are recognized in two or more households of center
attendees. In centers that do not provide care to children who wear diapers, IG
need be given only to classroom contacts of an index case-patient. When an out-
break occurs (i.e., hepatitis cases in three or more families), IG also should be
considered for members of households that have children (center attendees) in
diapers.
• Common-source exposure. If a food handler is diagnosed with hepatitis A, IG
should be administered to other food handlers at the same location. Administra-
tion of hepatitis A vaccine to these other food handlers might also be considered.
Because common-source transmission to patrons is unlikely, IG administration
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to patrons is usually not recommended but may be considered if a) during the
time when the food handler was likely to be infectious, the food handler both
directly handled uncooked foods or foods after cooking and had diarrhea or poor
hygienic practices and b) patrons can be identified and treated within 2 weeks
after the exposure. In settings where repeated exposures to HAV may have
occurred (e.g., institutional cafeterias), stronger consideration of IG use may be
warranted. In the event of a common-source outbreak, IG should not be adminis-
tered to exposed persons after cases have begun to occur because the 2-week
period during which IG is effective will have been exceeded.
• Schools, hospitals, and work settings. IG is not routinely indicated when a single
case occurs in an elementary or secondary school, an office, or in other work
settings, and the source of infection is outside the school or work setting. Simi-
larly, when a person who has hepatitis A is admitted to a hospital, staff should
not routinely be administered IG; instead, careful hygienic practices should be
emphasized. IG should be administered to persons who have close contact with
index patients if an epidemiologic investigation indicates HAV transmission has
occurred among students in a school or among patients or between patients and
staff in a hospital.
FUTURE CONSIDERATIONS
Both combination vaccines and new information are needed to achieve the goal of
substantially reducing the incidence of hepatitis A through routine vaccination of in-
fants or young children. Issues that should be addressed through clinical trials and
other studies include the following:
• Determining vaccine doses or schedules to overcome the reduced immune re-
sponse observed among infants who have passively acquired maternal anti-HAV;
• Developing vaccines that combine HAV antigen with other antigens to
more readily integrate hepatitis A vaccine into existing childhood vaccination
schedules;
• Determining the long-term protection afforded by hepatitis A immunization. This
determination will require the development of diagnostic assays that can distin-
guish between vaccine-induced antibody and antibody caused by natural
infection;
• Defining the most effective vaccination strategies for interrupting and preventing
communitywide outbreaks; and
• Determining whether hepatitis A vaccine will provide an adequate level of
postexposure protection from HAV infection.
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